Lesa L Aylward

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8708896/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phthalate esters in face masks and associated inhalation exposure risk. Journal of Hazardous Materials, 2022, 423, 127001.	12.4	37
2	Pesticide exposure in New Zealand school-aged children: Urinary concentrations of biomarkers and assessment of determinants. Environment International, 2022, 163, 107206.	10.0	12
3	Biomonitoring of per- and polyfluoroalkyl substances (PFAS) exposure in firefighters: Study design and lessons learned from stakeholder and participant engagement. International Journal of Hygiene and Environmental Health, 2022, 242, 113966.	4.3	3
4	Exposure and toxicity characterization of chemical emissions and chemicals in products: global recommendations and implementation in USEtox. International Journal of Life Cycle Assessment, 2021, 26, 899-915.	4.7	58
5	Comparison of lipid-normalised concentrations of persistent organic pollutants (POPs) between serum and adipose tissue. International Journal of Hygiene and Environmental Health, 2021, 236, 113801.	4.3	6
6	Exposure to selected preservatives in personal care products: case study comparison of exposure models and observational biomonitoring data. Journal of Exposure Science and Environmental Epidemiology, 2020, 30, 28-41.	3.9	10
7	Evaluation of human biomonitoring data in a health risk based context: An updated analysis of population level data from the Canadian Health Measures Survey. International Journal of Hygiene and Environmental Health, 2020, 223, 267-280.	4.3	47
8	How Many Urine Samples Are Needed to Accurately Assess Exposure to Non-Persistent Chemicals? The Biomarker Reliability Assessment Tool (BRAT) for Scientists, Research Sponsors, and Risk Managers. International Journal of Environmental Research and Public Health, 2020, 17, 9102.	2.6	7
9	Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery. Clinical Endocrinology, 2020, 93, 280-287.	2.4	8
10	Biomarkers of Environmental Exposures in Blood. , 2019, , 376-385.		6
11	Serum measures of hexabromocyclododecane (HBCDD) and polybrominated diphenyl ethers (PBDEs) in reproductive-aged women in the United Kingdom. Environmental Research, 2019, 177, 108631.	7.5	33
12	Pesticide metabolite concentrations in Queensland pre-schoolers – Exposure trends related to age and sex using urinary biomarkers. Environmental Research, 2019, 176, 108532.	7.5	24
13	Per- and polyfluoroalkyl substances (PFAS) in Australia: Current levels and estimated population reference values for selected compounds. International Journal of Hygiene and Environmental Health, 2019, 222, 387-394.	4.3	51
14	Biomonitoring Equivalents for interpretation of urinary iodine. Regulatory Toxicology and Pharmacology, 2018, 94, 40-46.	2.7	12
15	Screening-level Biomonitoring Equivalents for tiered interpretation of urinary 3-phenoxybenzoic acid (3-PBA) in a risk assessment context. Regulatory Toxicology and Pharmacology, 2018, 92, 29-38.	2.7	29
16	Advancements in Life Cycle Human Exposure and Toxicity Characterization. Environmental Health Perspectives, 2018, 126, 125001.	6.0	44
17	Cohort study of workers at a New Zealand agrochemical plant to assess the effect of dioxin exposure on mortality. BMJ Open, 2018, 8, e019243.	1.9	4
18	Temporal trends in serum polybrominated diphenyl ether concentrations in the Australian population, 2002–2013. Environment International, 2018, 121, 357-364.	10.0	18

#	Article	IF	CITATIONS
19	Integration of biomonitoring data into risk assessment. Current Opinion in Toxicology, 2018, 9, 14-20.	5.0	15
20	Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. International Journal of Hygiene and Environmental Health, 2018, 221, 1068-1075.	4.3	52
21	Persistent organic pollutants in infants and toddlers: Relationship between concentrations in matched plasma and faecal samples. Environment International, 2017, 107, 82-88.	10.0	5
22	Variation in urinary spot sample, 24 h samples, and longer-term average urinary concentrations of short-lived environmental chemicals: implications for exposure assessment and reverse dosimetry. Journal of Exposure Science and Environmental Epidemiology, 2017, 27, 582-590.	3.9	65
23	Mortality risk among workers with exposure to dioxins. Occupational Medicine, 2016, 66, 706-712.	1.4	7
24	Biomonitoring Equivalents for molybdenum. Regulatory Toxicology and Pharmacology, 2016, 77, 223-229.	2.7	40
25	Monthly variation in faeces:blood concentration ratio of persistent organic pollutants over the first year of life: a case study of one infant. Environmental Research, 2016, 147, 259-268.	7.5	7
26	Biomonitoring Equivalents for interpretation of silver biomonitoring data in a risk assessment context. International Journal of Hygiene and Environmental Health, 2016, 219, 521-526.	4.3	5
27	California biomonitoring data: Comparison to NHANES and interpretation in a risk assessment context. Regulatory Toxicology and Pharmacology, 2015, 73, 875-884.	2.7	12
28	Quantitative Property–Property Relationship for Screening-Level Prediction of Intrinsic Clearance: A Tool for Exposure Modeling for High-Throughput Toxicity Screening Data. Applied in Vitro Toxicology, 2015, 1, 140-146.	1.1	9
29	Elevated levels of PFOS and PFHxS in firefighters exposed to aqueous film forming foam (AFFF). Environment International, 2015, 82, 28-34.	10.0	130
30	Variation in Urinary Flow Rates According to Demographic Characteristics and Body Mass Index in NHANES: Potential Confounding of Associations between Health Outcomes and Urinary Biomarker Concentrations. Environmental Health Perspectives, 2015, 123, 293-300.	6.0	89
31	Biomonitoring Equivalents for interpretation of urinary fluoride. Regulatory Toxicology and Pharmacology, 2015, 72, 158-167.	2.7	42
32	Interpreting biomonitoring data for 2,4-dichlorophenoxyacetic acid: Update to Biomonitoring Equivalents and population biomonitoring data. Regulatory Toxicology and Pharmacology, 2015, 73, 765-769.	2.7	17
33	Persistent organic pollutants in matched breast milk and infant faeces samples. Chemosphere, 2015, 118, 309-314.	8.2	22
34	Age as a determinant of phosphate flame retardant exposure of the Australian population and identification of novel urinary PFR metabolites. Environment International, 2015, 74, 1-8.	10.0	211
35	Pooled biological specimens for human biomonitoring of environmental chemicals: Opportunities and limitations. Journal of Exposure Science and Environmental Epidemiology, 2014, 24, 225-232.	3.9	73
36	Urinary excretion and daily intake rates of diethyl phthalate in the general Canadian population. Science of the Total Environment, 2014, 500-501, 191-198.	8.0	29

#	Article	IF	CITATIONS
37	Application of pharmacokinetic modelling for 2,3,7,8-tetrachlorodibenzo- <i>p</i> -dioxin exposure assessment. SAR and QSAR in Environmental Research, 2014, 25, 873-890.	2.2	7
38	Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 2: Personal care product ingredients. Toxicology Letters, 2014, 231, 261-269.	0.8	96
39	Inter- and intra-individual variation in urinary biomarker concentrations over a 6-day sampling period. Part 1: Metals. Toxicology Letters, 2014, 231, 249-260.	0.8	42
40	Short term variability in urinary bisphenol A in Australian children. Environment International, 2014, 68, 139-143.	10.0	26
41	Relationships of Chemical Concentrations in Maternal and Cord Blood: A Review of Available Data. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2014, 17, 175-203.	6.5	77
42	Biomonitoring for POPs. , 2014, , 163-197.		0
43	Mode of action and dose–response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study. Critical Reviews in Toxicology, 2014, 44, 83-119.	3.9	69
44	Interpreting Estrogen Screening Assays in the Context of Potency and Human Exposure Relative to Natural Exposures to Phytoestrogens. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2014, 101, 114-124.	1.4	6
45	Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context. Toxicology Letters, 2014, 231, 126-134.	0.8	43
46	Sources of Variability in Biomarker Concentrations. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2014, 17, 45-61.	6.5	133
47	Biomonitoring Equivalents for selenium. Regulatory Toxicology and Pharmacology, 2014, 70, 333-339.	2.7	65
48	"Intrinsic―elimination rate and dietary intake estimates for selected indicator PCBs: Toxicokinetic modeling using serial sampling data in US subjects, 2005–2010. Chemosphere, 2014, 110, 48-52.	8.2	14
49	Population variation in biomonitoring data for persistent organic pollutants (POPs): An examination of multiple population-based datasets for application to Australian pooled biomonitoring data. Environment International, 2014, 68, 127-138.	10.0	24
50	Evaluation of urinary speciated arsenic in NHANES: Issues in interpretation in the context of potential inorganic arsenic exposure. Regulatory Toxicology and Pharmacology, 2014, 69, 49-54.	2.7	47
51	Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chemico-Biological Interactions, 2013, 204, 13-27.	4.0	37
52	Tissue distribution of dioxin-like compounds: Potential impacts on systemic relative potency estimates. Toxicology Letters, 2013, 220, 294-302.	0.8	10
53	Age-Related Trends in Urinary Excretion of Bisphenol A in Australian Children and Adults: Evidence from a Pooled Sample Study Using Samples of Convenience. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2013, 76, 1039-1055.	2.3	44
54	Elimination Rates of Dioxin Congeners in Former Chlorophenol Workers from Midland, Michigan. Environmental Health Perspectives, 2013, 121, 39-45.	6.0	20

#	Article	lF	CITATIONS
55	Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals. Environmental Health Perspectives, 2013, 121, 287-294.	6.0	126
56	Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: Application of chemical-specific screening criteria. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 24-34.	3.9	19
57	Interpreting variability in population biomonitoring data: Role of elimination kinetics. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 398-408.	3.9	78
58	Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chemico-Biological Interactions, 2012, 200, 45-64.	4.0	51
59	2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches. Regulatory Toxicology and Pharmacology, 2012, 64, 481-489.	2.7	20
60	Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere, 2012, 89, 487-493.	8.2	34
61	Development of Screening Tools for the Interpretation of Chemical Biomonitoring Data. Journal of Toxicology, 2012, 2012, 1-10.	3.0	11
62	Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH. International Journal of Hygiene and Environmental Health, 2012, 215, 238-241.	4.3	9
63	Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents. International Journal of Hygiene and Environmental Health, 2012, 215, 145-148.	4.3	37
64	Biomonitoring Equivalents for benzene. Regulatory Toxicology and Pharmacology, 2012, 62, 62-73.	2.7	30
65	Urinary DEHP metabolites and fasting time in NHANES. Journal of Exposure Science and Environmental Epidemiology, 2011, 21, 615-624.	3.9	34
66	Human biomonitoring as a pragmatic tool to support health risk management of chemicals – Examples under the EU REACH programme. Regulatory Toxicology and Pharmacology, 2011, 59, 125-132.	2.7	49
67	Biomonitoring Equivalents for 2,2′,4,4′,5-pentabromodiphenylether (PBDE-99). Regulatory Toxicology and Pharmacology, 2011, 60, 165-171.	2.7	20
68	Biomonitoring Equivalents for DDT/DDE. Regulatory Toxicology and Pharmacology, 2011, 60, 172-180.	2.7	47
69	Biomonitoring Equivalents for di-isononyl phthalate (DINP). Regulatory Toxicology and Pharmacology, 2011, 60, 181-188.	2.7	37
70	Biomonitoring Equivalents for deltamethrin. Regulatory Toxicology and Pharmacology, 2011, 60, 189-199.	2.7	35
71	Assessment of margin of exposure based on biomarkers in blood: An exploratory analysis. Regulatory Toxicology and Pharmacology, 2011, 61, 44-52.	2.7	9
72	Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). International Journal of Hygiene and Environmental Health, 2011, 214, 179-187.	4.3	30

Lesa L Aylward

#	Article	IF	CITATIONS
73	Human biomonitoring assessment values: Approaches and data requirements. International Journal of Hygiene and Environmental Health, 2011, 214, 348-360.	4.3	156
74	Consideration of dosimetry in evaluation of <scp>ToxCast</scp> â,,¢ data. Journal of Applied Toxicology, 2011, 31, 741-751.	2.8	19
75	Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) – Application of steady-state PBPK model solutions. Regulatory Toxicology and Pharmacology, 2010, 58, 33-44.	2.7	30
76	Biomonitoring Equivalents for inorganic arsenic. Regulatory Toxicology and Pharmacology, 2010, 58, 1-9.	2.7	71
77	Biomonitoring equivalents for hexachlorobenzene. Regulatory Toxicology and Pharmacology, 2010, 58, 25-32.	2.7	27
78	Biomonitoring Equivalents for triclosan. Regulatory Toxicology and Pharmacology, 2010, 58, 10-17.	2.7	35
79	Biomonitoring Equivalents for bisphenol A (BPA). Regulatory Toxicology and Pharmacology, 2010, 58, 18-24.	2.7	65
80	TCDD exposure estimation for workers at a New Zealand 2,4,5-T manufacturing facility based on serum sampling data. Journal of Exposure Science and Environmental Epidemiology, 2010, 20, 417-426.	3.9	7
81	Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999–2004. Journal of Exposure Science and Environmental Epidemiology, 2010, 20, 255-262.	3.9	34
82	THREE AUTHORS REPLY. American Journal of Epidemiology, 2010, 171, 130-131.	3.4	0
83	Biomonitoring Data for 2,4-Dichlorophenoxyacetic Acid in the United States and Canada: Interpretation in a Public Health Risk Assessment Context Using Biomonitoring Equivalents. Environmental Health Perspectives, 2010, 118, 177-181.	6.0	36
84	Advancing Exposure Characterization for Chemical Evaluation and Risk Assessment. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2010, 13, 299-313.	6.5	87
85	Correlates of serum dioxin to self-reported exposure factors. Environmental Research, 2010, 110, 131-136.	7.5	10
86	Estimates of Cancer Potency of 2,3,7,8-Tetrachlorodibenzo(p)dioxin Using Linear and Nonlinear Dose-Response Modeling and Toxicokinetics. Toxicological Sciences, 2009, 112, 490-506.	3.1	23
87	Mortality Rates Among Trichlorophenol Workers With Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. American Journal of Epidemiology, 2009, 170, 501-506.	3.4	53
88	Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). Regulatory Toxicology and Pharmacology, 2009, 55, 249-258.	2.7	38
89	Derivation of Biomonitoring Equivalents for cyfluthrin. Regulatory Toxicology and Pharmacology, 2009, 55, 268-275.	2.7	25
90	Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). Regulatory Toxicology and Pharmacology, 2009, 55, 259-267.	2.7	56

#	Article	IF	CITATIONS
91	Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context. Journal of Applied Toxicology, 2009, 29, 275-288.	2.8	81
92	Hepatic P450 Enzyme Activity, Tissue Morphology and Histology of Mink (Mustela vison) Exposed to Polychlorinated Dibenzofurans. Archives of Environmental Contamination and Toxicology, 2009, 57, 416-425.	4.1	6
93	Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy. Journal of Exposure Science and Environmental Epidemiology, 2009, 19, 634-642.	3.9	72
94	Perspective on serum dioxin levels in the United States: an evaluation of the NHANES data. Journal of Exposure Science and Environmental Epidemiology, 2009, 19, 435-441.	3.9	37
95	Mortality Rates Among Workers Exposed to Dioxins in the Manufacture of Pentachlorophenol. Journal of Occupational and Environmental Medicine, 2009, 51, 1212-1219.	1.7	30
96	Mortality in Workers Exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin at a Trichlorophenol Plant in New Zealand. Journal of Occupational and Environmental Medicine, 2009, 51, 1049-1056.	1.7	27
97	Nondestructive Scat Sampling in Assessment of Mink (Mustela vison) Exposed to Polychlorinated Dibenzofurans (PCDFs). Archives of Environmental Contamination and Toxicology, 2008, 55, 529-537.	4.1	3
98	Introduction to the Biomonitoring Equivalents Pilot Project: Development of guidelines for the derivation and communication of Biomonitoring Equivalents. Regulatory Toxicology and Pharmacology, 2008, 51, S1-S2.	2.7	12
99	Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S4-S15.	2.7	147
100	Biomonitoring Equivalents (BE) dossier for trihalomethanes. Regulatory Toxicology and Pharmacology, 2008, 51, S68-S77.	2.7	18
101	Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regulatory Toxicology and Pharmacology, 2008, 51, S37-S48.	2.7	51
102	Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S16-S26.	2.7	99
103	Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). Regulatory Toxicology and Pharmacology, 2008, 51, S49-S56.	2.7	82
104	Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). Regulatory Toxicology and Pharmacology, 2008, 51, S27-S36.	2.7	26
105	Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regulatory Toxicology and Pharmacology, 2008, 51, S57-S67.	2.7	36
106	A pilot study of oral bioavailability of dioxins and furans from contaminated soils: Impact of differential hepatic enzyme activity and species differences. Chemosphere, 2008, 70, 1774-1786.	8.2	47
107	Comment on "Chronic Disease and Early Exposure to Air-Borne Mixtures. 2. Exposure Assessmentâ€ Environmental Science & Technology, 2008, 42, 2201-2201.	10.0	0
108	Toxicokinetics Of 2,3,7,8-TCDF and 2,3,4,7,8-PeCDF in Mink (Mustela vison) at Ecologically Relevant Exposures. Toxicological Sciences, 2008, 105, 33-43.	3.1	16

#	Article	IF	CITATIONS
109	Estimates of Cancer Potency of 2,3,4,7,8-Pentachlorodibenzofuran Using Both Nonlinear and Linear Approaches. Toxicological Sciences, 2008, 106, 519-537.	3.1	6
110	Derivation of Biomonitoring Equivalent (BE) Values for 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (TCDD) and Related Compounds: A Screening Tool for Interpretation of Biomonitoring Data in a Risk Assessment Context. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2008, 71, 1499-1508.	2.3	20
111	A Margin-of-Exposure Approach to Assessment of Noncancer Risks of Dioxins Based on Human Exposure and Response Data. Environmental Health Perspectives, 2008, 116, 1344-1351.	6.0	11
112	Environmental chemicals in people: challenges in interpreting biomonitoring information. Journal of Environmental Health, 2008, 70, 61-4.	0.5	9
113	Is Age an Independent Risk Factor for Chemically Induced Acute Myelogenous Leukemia in Children?. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2007, 10, 379-400.	6.5	21
114	Age-specific Reference Ranges for Polychlorinated Biphenyls (PCB) Based on the NHANES 2001–2002 Survey. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2007, 70, 1873-1877.	2.3	37
115	Estimating Past Dioxin Exposure: Response to Steenland and Bartell. Risk Analysis, 2007, 27, 9-10.	2.7	Ο
116	Biomonitoring equivalents: A screening approach for interpreting biomonitoring results from a public health risk perspective. Regulatory Toxicology and Pharmacology, 2007, 47, 96-109.	2.7	219
117	A mechanism-based cancer risk assessment for 1,4-dichlorobenzene. Regulatory Toxicology and Pharmacology, 2007, 49, 138-148.	2.7	26
118	Human Response to Dioxin: Aryl Hydrocarbon Receptor (AhR) Molecular Structure, Function, and Dose-Response Data for Enzyme Induction Indicate an Impaired Human AhR. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2006, 9, 147-171.	6.5	85
119	TCDD Exposure-Response Analysis and Risk Assessment. Risk Analysis, 2006, 26, 1059-1071.	2.7	23
120	Sex ratio of the offspring of Sprague–Dawley rats exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in utero and lactationally in a three-generation study. Toxicology and Applied Pharmacology, 2006, 216, 29-33.	2.8	16
121	Does dioxin exert toxic effects in humans at or near current background body levels?: an evidence-based conclusion. Human and Experimental Toxicology, 2006, 25, 99-105.	2.2	13
122	Relative Cancer Potencies of Selected Dioxin-Like Compounds on a Body-Burden Basis: Comparison to Current Toxic Equivalency Factors (TEFs). Journal of Toxicology and Environmental Health - Part A: Current Issues, 2006, 69, 907-917.	2.3	9
123	Exposure Reconstruction for the TCDD-Exposed NIOSH Cohort Using a Concentration- and Age-Dependent Model of Elimination. Risk Analysis, 2005, 25, 945-956.	2.7	33
124	Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. Journal of Exposure Science and Environmental Epidemiology, 2005, 15, 51-65.	3.9	127
125	Issues in Risk Assessment for Developmental Effects of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and Related Compounds. Toxicological Sciences, 2005, 87, 3-10.	3.1	17
126	RAPID COMMUNICATION: BACKGROUND CONCENTRATIONS OF DIOXINS, FURANS, AND PCBs IN SPRAGUE-DAWLEY RATS AND JUVENILE SWINE. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 845-850.	2.3	4

#	Article	IF	CITATIONS
127	An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD). Regulatory Toxicology and Pharmacology, 2004, 40, 9-17.	2.7	34
128	Dioxin risks in perspective: past, present, and future. Regulatory Toxicology and Pharmacology, 2003, 37, 202-217.	2.7	111
129	Re: analysis of dioxin cancer threshold Environmental Health Perspectives, 2003, 111, A510.	6.0	0
130	Temporal trends in human TCDD body burden: Decreases over three decades and implications for exposure levels. Journal of Exposure Science and Environmental Epidemiology, 2002, 12, 319-328.	3.9	98
131	Comment on "Relative Susceptibility of Animals and Humans to the Cancer Hazard Posed by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Using Internal Measures of Dose― Environmental Science & Technology, 1998, 32, 549-550.	10.0	1
132	Response to Comment on "Relative Susceptibility of Animals and Humans to the Cancer Hazard Posed by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Using Internal Measures of Dose― Environmental Science & Technology, 1998, 32, 551-552.	10.0	1
133	The relative susceptibility of animals and humans to the carcinogenic hazard posed by exposure to 2,3,7,8-TCDD: An analysis using standard and internal measures of dose. Chemosphere, 1997, 34, 1507-1522.	8.2	10
134	Relative Susceptibility of Animals and Humans to the Cancer Hazard Posed by 2,3,7,8-Tetrachlorodibenzo-p- dioxin Using Internal Measures of Dose. Environmental Science & Technology, 1996, 30, 3534-3543.	10.0	51

9